Related Experiment Video
Updated: Aug 11, 2026

Real-time Imaging of Myeloid Cells Dynamics in ApcMin/+ Intestinal Tumors by Spinning Disk Confocal Microscopy
Published on: October 6, 2014
Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse
S Sale1, R G Tunstall, K C Ruparelia
1Cancer Biomarkers and Prevention Group, Department of Cancer Studies, University of Leicester, Leicester, UK.
Abstract:
DMU-135 (3,4-Methylenedioxy-3',4',5'-trimethoxy chalcone) is a novel anticancer prodrug designed to be activated into a potent tyrosine kinase inhibitor by the tumour selective enzyme activity of the cytochrome P450 enzyme CYP1B1. CYP1B1 is selectively expressed in a wide variety of tumours including colon. The hypothesis was tested that DMU-135 would inhibit Apc(Min/+) mouse gastrointestinal adenoma formation. From 4-18 weeks of age animals received DMU-135 (0.2% w:w) in AIN93G diet. DMU-135 was well tolerated, induced no systemic side-effects and reduced adenoma multiplicity by 46 +/- 18.3% compared to controls (p < 0.001). Further characterisation of this promising chemopreventive agent is required.
Insights
DMU-135, a novel anticancer prodrug, effectively reduced gastrointestinal adenoma formation in mice by 46%. This promising chemopreventive agent shows potential for cancer treatment by targeting tumor-specific enzymes.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Cytochrome P450 enzyme CYP1B1 is selectively expressed in various tumors, including colon cancer.
- DMU-135 is a novel anticancer prodrug designed for targeted activation by CYP1B1.
Purpose of the Study:
- To investigate the chemopreventive efficacy of DMU-135 in inhibiting gastrointestinal adenoma formation in Apc(Min/+) mice.
Main Methods:
- Apc(Min/+) mice were administered DMU-135 (0.2% w:w) in their diet from 4 to 18 weeks of age.
- Adenoma multiplicity was compared between the treatment group and control group.
Main Results:
- DMU-135 was well-tolerated and did not induce systemic side-effects.
- DMU-135 significantly reduced adenoma multiplicity by 46 +/- 18.3% (p < 0.001) compared to controls.
Conclusions:
- DMU-135 demonstrates significant chemopreventive activity against gastrointestinal adenoma formation.
- Further characterization of DMU-135 as a promising chemopreventive agent is warranted.

![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)